Remove 2019 Remove Disease Remove Pharmacokinetics Remove Trials
article thumbnail

New molecular insights on medical cannabis

Drug Target Review

2 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 1-5 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. Mediators of Inflammation. 2017;2017:1–15.

article thumbnail

Preparing the next generation of drug discovery scientists

Drug Discovery World

The new Clinical Pharmacology degree was launched in 2019 by Professors Emma Baker and Iain Greenwood and aims to take a holistic view of the development of drugs and create graduates that will stand out in the job market. These are: Fundamentals of science: Understanding how the body works and what goes wrong in disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

The Pharma Data

This Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with elevated plasma triglyceride levels. A Phase 2b study was initiated in July 2019 (ICONA) to study the efficacy of icosabutate in NASH. SEFA-1024 is one of NST’s three SEFA programs.

Trials 40
article thumbnail

Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a ‘AMBITION’ Clinical Trial for NASH

The Pharma Data

The open-label Phase 2a ‘AMBITION’ study is designed to assess safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy of 75 mg and 225 mg CRV431, administered orally to F2 and F3 NASH patients (n=18/dosing group), once daily for 28 days.

article thumbnail

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH

The Pharma Data

NASH, which is a severe form of non-alcoholic fatty liver disease affects approximately 17 million people in the U.S. The AMBITION trial is the first placebo-controlled study of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis. and is a leading cause of liver transplantation. ” About Hepion Pharmaceuticals.

article thumbnail

Looking beyond traditional oncogenic pathways to break cancer resistance

Drug Target Review

Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment. 8 Preliminary data from the trial have shown good safety and tolerability for TT125-802, with confirmed preliminary target engagement in surrogate tissues such as hair follicles and peripheral blood mononuclear cells.

article thumbnail

Etrasimod

New Drug Approvals

1 Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal tract, thus causing diffuse mucosal inflammation. June 2019). 11] SYN ACS Med. twitter +919321316780 call whatsaapp EMAIL.

FDA 57